Loading...
Loading...
Sucampo Pharmaceuticals, Inc.
SCMP (SPI) and Takeda Pharmaceuticals
U.S.A., Inc. (TPUSA) announced today that the United States (U.S.) Food and
Drug Administration (FDA) has approved Sucampo's supplemental new drug
application (sNDA) for AMITIZA^® (lubiprostone) (24 mcg twice daily) as the
first and only oral medication for the treatment of opioid-induced
constipation (OIC) in adult patients with chronic, non-cancer pain. The
effectiveness of AMITIZA in the treatment of opioid-induced constipation in
patients taking diphenylheptane opioids (e.g., methadone) has not been
established.
This is the third indication for AMITIZA, which is also approved in the U.S.
for the treatment of chronic idiopathic constipation (CIC) in adults (24 mcg
twice daily) and irritable bowel syndrome with constipation (IBS-C) in adult
women (8 mcg twice daily). There are more than 200 million prescriptions for
opioid use in the U.S. annually, and a substantial number of these
prescriptions are for non-cancer chronic pain. ^ Scientific literature
indicates that approximately 40-80% of patients taking opioids chronically for
non-cancer pain report constipation.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in